The Food and Drug Administration of the United States has approved crizotinib for advanced non-small cell lung cancer with ALK or ROS1 fusion.13 Response to crizotinib has been documented in case reports of patients with lung adenocarcinoma with MET fusion. Here, ALK is linked to non-small cell lung carcinoma.